(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 30 June 2005 (30.06.2005)

PCT

(10) International Publication Number WO 2005/059109 A3

(51) International Patent Classification: C12Q 1/68 (2006.01) C07H 21/02 (2006.01)

(21) International Application Number:

PCT/US2004/042258

(22) International Filing Date:

12 December 2004 (12.12.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/530,101

15 December 2003 (15.12.2003) US

- (71) Applicant (for all designated States except US): THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 1111 Franklin Street, 12th floor, Oakland, CA 94607-5200 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): CHEN, Charlie, D. [CN/US]; 3300 Sawtelle Blvd. #306, LA, CA 90066 (US). SAWYERS, Charles, L. [US/US]; 3343 Mondeville Canyon Rd.,, LA, CA 90049 (US).


- (74) Agent: GATES, George, H.; Gates & Cooper LLP, Suite 1050, 6701 Center Drive West, Los Angeles, CA 90045 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

[Continued on next page]

(54) Title: MOLECULAR SIGNATURE OF THE PTEN TUMOR SUPPRESSOR



(57) Abstract: The present invention relates to the identification a molecular signature for PTEN tumor suppressor. The molecular signature comprising a gene or genes that are of use for diagnosis, prognosis, drug research and development and therapeutics. Specifically, the present invention relates to identication of IGFBP2 gene, its mRNA and/or protein products that closely associate with PTEN mutations. The present invention further demonstrates that IGFBP2 expression is negatively regulated by PTEN, positively regulated by PI3K and Akt activation, that IGFBP2 plays a functional role in the PTEN signaling and is required for Akt transformation. The use of IGFBP2 gene, its gene product such as its RNA transcript, protein and molecular probes in diagnosis, prognosis, drug discovery and validation and therapeutic target and therapeutics is also contemplated.

WO 2005/059109 A3



- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 28 September 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/42258

A. CLASSIFICATION OF SUBJECT MATTER				
IPC:	C12Q 1/68(2006.01)			
	C07H 21/02(2006.01)			
	00,1121,02(2000.01)			
USPC:	435/6			
		sianal alassification and IDC		
Accordin	g to International Patent Classification (IPC) or to both na	nonal classification and IPC		
B. F	ELDS SEARCHED			
Minimun	n documentation searched (classification system followed b	y classification symbols)		
U.S.	: 435/6, 91.1, 91.2, 183; 436/94; 536/23.1, 24.3, 24.33, 25	5.3		
Documen	tation searched other than minimum documentation to the	extent that such documents are included in	the fields searched	
Electroni	c data base consulted during the international search (name	of data base and where procticable sourch	torms used)	
	e Continuation Sheet	of data base and, where practicable, search	terms used)	
r lease Se	e Continuation Sheet			
		·		
C. D	OCUMENTS CONSIDERED TO BE RELEVANT			
				
Category	Citation of document, with indication, where a	ppropriate, of the relevant passages	Relevant to claim No.	
E	US 2006/0127902 A1 (MADDEN et al) 15 June 200	6 (15.06.2006), see whole	claims 1-20	
_	document, especially see [0008] in pages 4 -6 and cla		***************************************	
	document, soponari, see [0000] iii pages i o and en	22 puges 133 101		
		İ		
	ł	·		
		1		
		İ	İ	
	· ·			
			İ	
			•	
			•	
Fur	ther documents are listed in the continuation of Box C.	See patent family annex.		
<u> </u>				
-	Special categories of cited documents:	"T" later document published after the internal date and not in conflict with the application.	ational filing date or priority	
"A" docu	ment defining the general state of the art which is not considered to be of	principle or theory underlying the inventi		
	cular relevance			
		"X" document of particular relevance; the cla	imed invention cannot be	
"E" earli	er application or patent published on or after the international filing date	considered novel or cannot be considered when the document is taken alone	to involve an inventive step	
"L" docu	ment which may throw doubts on priority claim(s) or which is cited to	when the document is taken alone		
	lish the publication date of another citation or other special reason (as	"Y" document of particular relevance; the cla	imed invention cannot be	
spec	ified)	considered to involve an inventive step w		
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		with one or more other such documents,	such combination being	
"O" docu	ment referring to an oral disclosure, use, exhibition or other means	obvious to a person skilled in the art		
"P" docu	ment published prior to the international filing date but later than the	"&" document member of the same patent fan	nilv	
	ity date claimed	· · · · · · · · · · · · · · · · · · ·		
Date of th	e actual completion of the international search	Date of mailing of the international search	report	
Date of th	e actual completion of the international scarci		report	
26 June 2006 (26.06.2006) U7 AUG 2006				
Name and	I mailing address of the ISA/US	Authorized officer	1 1 2	
(411)	Mail Stop PCT, Attn: ISA/US	1.11.	(V V) / s	
Commissioner for Patents		Frank Lu Della Callent for		
P.O. Box 1450			_ //	
	Alexandria, Virginia 22313-1450	Telephone No. 703-308-0196	<i>l/</i> 1	
Facsimile No. (571) 273-3201				

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/42258 .

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)				
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:				
	Claims Nos.: secause they relate to subject matter not required to be searched by this Authority, namely:			
t	Claims Nos.: Decause they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:			
	Claims Nos.: pecause they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).			
Box No. III	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)			
This Internation Please Sec Con	nal Searching Authority found multiple inventions in this international application, as follows: tinuation Sheet			
2.	As all required additional search fees were timely paid by the applicant, this international search report covers all earchable claims. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of any additional fees. As only some of the required additional search fees were timely paid by the applicant, this international search report overs only those claims for which fees were paid, specifically claims Nos.:			
	payment of a protest fee. The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.			
	No protest accompanied the payment of additional search fees.			

INTERNATIONAL SEARCH REPORT

International application No. PCT/US04/42258

BOX III. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claims 1-20, drawn to a method of profiling a tumor/cancer in human tissue specimens wherein said gene is insulin-like growth factor binding protein 2.

Group II, claims 21-43, drawn to a method of screening a compound inhibits cancer cell growth.

Group III, claims 44-58, drawn to an assay kit of profiling a tumor/cancer in human tissue specimens.

Group IV, claims 59 and 60, drawn to a therapeutic useful antibody against insulin-like growth factor binding protein 2 or IGFBP2.

Note that, since claims 8 and 9 has a lot of genes which have different structures and different functions, Group I is divided to many different subgroups each subgroup has different genes, applicant requires to select a single gene for the examination. Applicant is advised that examination will be restricted to only elected gene and should not to be construed as a species election.

The inventions listed as Groups I to IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because they lack the same or corresponding special technical features. For example, profiling a tumor/cancer in human tissue specimens in claim 1 of Group I is not required for Group II while screening a compound that inhibits cancer cell growth in claim 21 of Group II is not required for Group I.

Groups I and III do not relate to a single general inventive concept under PCT Rule 13.1 because the technical feature linking Groups I and III is not special. For example, an assay kit of Group III is not a contribution over the prior art since a kit containing antibodies against HC gp-39 in US Patent No. 5,726,06 (published on March 10, 1998) reads an assay kit of Group III.

Groups I and IV do not relate to a single general inventive concept under PCT Rule 13.1 because the technical feature linking Groups I and III is not special. For example, profiling a tumor/cancer in human tissue specimens in claim 1 of Group I is not required for Group IV while a therapeutic useful antibody against insulin-like growth factor binding protein 2 in claim 59 of Group IV is not required for Group I.

Groups II and III do not relate to a single general inventive concept under PCT Rule 13.1 because the technical feature linking Groups II and III is not special. For example, an assay kit of Group III is not a contribution over the prior art since a kit containing antibodies against HC gp-39 in US Patent No. 5,726,06 (published on March 10, 1998) reads an assay kit of Group III.

Groups II and IV do not relate to a single general inventive concept under PCT Rule 13.1 because they lack the same or corresponding special technical features. For example, screening a compound that inhibits cancer cell growth in claim 21 of Group II is not required for Group IV while a therapeutic useful antibody against insulin-like growth factor binding protein 2 in claim 59 of Group IV is not required for Group II.

Groups III and IV do not relate to a single general inventive concept under PCT Rule 13.1 because they lack the same or corresponding special technical features. For example, an assay kit in claim 44 of Group III is not required for Group IV while a therapeutic useful antibody against insulin-like growth factor binding protein 2 in claim 59 of Group IV is not required for Group III.

INTERNATIONAL SEARCH REPORT	PCT/US04/42258
Continuation of B. FIELDS SEARCHED Item 3: STN and EAST	
Search terms: cancer or tumor, express\$, gene, human, compound or reagent of	or substance, and insulin-like growth factor binding protein